ADCT
Adc Therapeutics SA

1,249
Mkt Cap
$500.55M
Volume
523,473.00
52W High
$4.98
52W Low
$1.05
PE Ratio
-3.28
ADCT Fundamentals
Price
$3.97
Prev Close
$3.94
Open
$3.99
50D MA
$4.00
Beta
1.59
Avg. Volume
772,271.51
EPS (Annual)
-$1.12
P/B
-2.67
Rev/Employee
$421,538.86
$626.76
Loading...
Loading...
News
all
press releases
ADC Therapeutics (NYSE:ADCT) Shares Gap Up on Analyst Upgrade
ADC Therapeutics (NYSE:ADCT) Shares Gap Up Following Analyst Upgrade...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
ADC Therapeutics (NYSE:ADCT) Price Target Raised to $8.00
HC Wainwright boosted their target price on shares of ADC Therapeutics from $7.00 to $8.00 and gave the stock a "buy" rating in a research report on Monday...
MarketBeat·2d ago
News Placeholder
Heights Capital Management Inc. Has $1.31 Million Position in ADC Therapeutics SA $ADCT
Heights Capital Management Inc. lessened its holdings in ADC Therapeutics SA (NYSE:ADCT - Free Report) by 88.5% during the third quarter, according to the company in its most recent filing with the...
MarketBeat·8d ago
News Placeholder
Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year?
Here is how ADC Therapeutics SA (ADCT) and ALX Oncology Holdings Inc. (ALXO) have performed compared to their sector so far this year.
Zacks·12d ago
News Placeholder
ADC Therapeutics (NYSE:ADCT) Shares Down 9.2% - Should You Sell?
ADC Therapeutics (NYSE:ADCT) Trading Down 9.2% - Here's Why...
MarketBeat·13d ago
News Placeholder
ADC Therapeutics (NYSE:ADCT) Reaches New 12-Month High Following Strong Earnings
ADC Therapeutics (NYSE:ADCT) Hits New 1-Year High After Strong Earnings...
MarketBeat·15d ago
News Placeholder
ADC Therapeutics Q4 Earnings Call Highlights
ADC Therapeutics (NYSE:ADCT) outlined a 2025 strategy centered on expanding ZYNLONTA while significantly reducing costs, and management pointed investors to multiple clinical and regulatory catalysts...
MarketBeat·15d ago
News Placeholder
ADC Therapeutics (NYSE:ADCT) Shares Gap Up After Strong Earnings
ADC Therapeutics (NYSE:ADCT) Shares Gap Up on Strong Earnings...
MarketBeat·15d ago
News Placeholder
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates
ADC Therapeutics (ADCT) delivered earnings and revenue surprises of +87.50% and +20.41%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·15d ago
News Placeholder
ADC Therapeutics Posts Narrower Loss In Q4
(RTTNews) - ADC Therapeutics SA (ADCT) reported a net loss for the quarter ended December 31, 2025, of $6.4 million, or a net loss of $0.04 per share, as compared to net loss of $30.7 million, or a...
Nasdaq News: Markets·15d ago
<
1
2
...
>

Latest ADCT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.